- Sector
- Healthcare
- Industry
- Biotechnology
Highlights
- Market Cap
- $3.99B
- Enterprise Value
- $3.73B
- EPS (TTM)
- -$2.57
- EBITDA (TTM)
- -$206.36M
- Year Range
- $6.40 - $39.16
- Target Price
- $35.63
- ROA (TTM)
- -59.19%
- ROE (TTM)
- -85.19%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DFTX Performance Chart
Definium Therapeutics, Inc (DFTX) is up 173.9% since the beginning of the year. At $37 per share, DFTX is trading 6.4% below its 52-week high of $39.
Loading charts...
Returns By Period
Definium Therapeutics, Inc (DFTX) has returned 173.86% so far this year and 420.14% over the past 12 months.
Definium Therapeutics, Inc
- 1D
- 49.80%
- 1M
- 62.98%
- YTD
- 173.86%
- 6M
- 175.71%
- 1Y
- 420.14%
- 3Y*
- 123.15%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
DFTX Monthly Returns History
Based on dividend-adjusted daily data since Jul 11, 2022, DFTX's average daily return is +0.28%, while the average monthly return is +5.98%. At this rate, an investment would double in approximately 1.0 years.
Historically, 58% of months were positive and 42% were negative. The best month was Mar 2024 with a return of +64.5%, while the worst month was Sep 2022 at -70.1%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.
On a daily basis, DFTX closed higher 49% of trading days. The best single day was Mar 7, 2024 with a return of +51.5%, while the worst single day was Sep 28, 2022 at -47.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 26.06% | 3.38% | 8.31% | 15.77% | 10.56% | 51.59% | 173.86% | ||||||
| 2025 | -2.44% | -1.03% | -12.95% | 9.23% | 13.62% | -10.61% | 40.06% | -2.31% | 32.77% | 20.44% | -10.92% | 5.85% | 92.39% |
| 2024 | 5.46% | 48.06% | 64.48% | 1.28% | -7.56% | -18.07% | 28.43% | -34.56% | -6.11% | 10.72% | 29.68% | -14.81% | 90.16% |
| 2023 | 55.00% | 9.09% | -14.78% | 20.50% | -7.33% | 0.85% | 38.10% | -15.82% | -24.58% | -18.21% | 28.91% | 10.91% | 66.36% |
| 2022 | 0.68% | 12.47% | -70.14% | -16.29% | -12.97% | -13.73% | -78.74% |
Benchmark Metrics
Definium Therapeutics, Inc has an annualized alpha of 55.54%, beta of 1.43, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since July 11, 2022.
- This stock captured 291.06% of S&P 500 Index gains and 188.07% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 55.54%
- Beta
- 1.43
- R²
- 0.07
- Upside Capture
- 291.06%
- Downside Capture
- 188.07%
Return for Risk
Risk / Return Rank
DFTX ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Definium Therapeutics, Inc (DFTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DFTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.36 | ||
| Sortino ratioReturn per unit of downside risk | +2.67 | ||
| Omega ratioGain probability vs. loss probability | 1.64 | 1.37 | +0.27 |
| Calmar ratioReturn relative to maximum drawdown | 17.09 | 2.78 | +14.30 |
| Martin ratioReturn relative to average drawdown | 53.86 | 12.44 | +41.42 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Definium Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Definium Therapeutics, Inc was 86.01%, occurring on Dec 28, 2022. Recovery took 764 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -86.01%Dec 2022 | 4mo 11d | 3y 19d | 3y 5moAug 2022 - Jan 2026 |
Bear market2022 | -23.66%Aug 2022 | 19d | 9d | 28dJul 2022 - Aug 2022 |
2026 correction2026 | -16.02%May 2026 | 27d | 10d | 1mo 7dApr 2026 - May 2026 |
2026 correction2026 | -13.60%Feb 2026 | 10d | 24d | 1mo 4dFeb 2026 - Mar 2026 |
Bear market2022 | -8.16%Jul 2022 | 0s | 7d | 7dJul 2022 - Jul 2022 |
Drawdown Indicators
| DFTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.01% | -56.78% | -29.23% |
Max Drawdown (1Y)Largest decline over 1 year | -24.79% | -9.10% | -15.69% |
Max Drawdown (3Y)Largest decline over 3 years | -58.38% | -18.90% | -39.48% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | 0.00% | -1.80% | +1.80% |
Average DrawdownAverage peak-to-trough decline | -50.97% | -10.71% | -40.26% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.86% | 2.03% | +5.83% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Definium Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Definium Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DFTX in comparison with other companies in the Biotechnology industry. Currently, DFTX has a P/B value of 14.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DFTX
Add Definium Therapeutics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DFTX